Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 19/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.80 |
| ▸ | PDE2A | O00408 | 1/20 | 0.80 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.80 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.80 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.80 |
| ▸ | BRD4 | O60885 | 1/20 | 0.80 |
| ▸ | PDE5A | O76074 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | PIM1 | P11309 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13700043 | 1.00 | PRKDC (0.80) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| Ly-294002 SCHEMBL94377 | 0.89 | PRKDC (1.00) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| Ly-294002 SCHEMBL29424167 | 0.89 | PRKDC (1.00) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL437654 | 0.88 | PRKDC (0.88) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL31060584 | 0.88 | PRKDC (1.00) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL12452458 | 0.88 | PRKDC (0.80) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL4418721 | 0.88 | PRKDC (0.80) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL31061281 | 0.88 | PRKDC (1.00) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| Ly-294002 SCHEMBL5078472 | 0.88 | ALDH1A1 (1.00) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD | |
| SCHEMBL13496867 | 0.88 | PRKDC (0.97) | PRKDCKDM4EALDH1A1SMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072355-A1 | METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO | BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | claimed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117751182-A | Method for amplifying human granulocyte-macrophage progenitor cells and application thereof | 南加利福尼亚大学 | 2024-03-22 | — | — | CN | claimed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | claimed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| EP-4677064-A1 | METHODS AND COMPOSITIONS FOR IN VITRO HAEMATOPOIESIS AND LYMPHOPOIESIS | Murdoch Children's Research Institute (AU) | 2026-01-14 | — | — | EP | disclosed |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2025104184-A1 | METHOD OF GENERATING HAEMATOPOIETIC CELLS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| EP-3474849-B1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DIABETES | BROAD INST INC (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025072355-A1 | METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO | BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240408098-A1 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | MIRATI THERAPEUTICS, INC | 2024-12-12 | — | — | US | disclosed |
| US-11491174-B2 | Induction of synthetic lethality with epigenetic therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-11-08 | — | — | US | disclosed |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220221779-A1 | ISOLATED HUMAN LUNG PROGENITOR CELLS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2022-07-14 | — | — | US | disclosed |
| WO-2022082108-A1 | COMPOSITIONS FOR INDUCING TUMOR IMMUNITY AND REDUCING DRUG TOLERANCE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491174-B2 | Induction of synthetic lethality with epigenetic therapy | MCL1, BAD, ACIN1 | PRKDC 1003/4885KDM4E 458/4885ALDH1A1 3018/4885 |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | MCL1, BAD, ACIN1 | PRKDC 1003/4885KDM4E 458/4885ALDH1A1 3018/4885 |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | SLC2A2, SLC2A1, SLC5A2 | PRKDC 4507/4885KDM4E 4178/4885ALDH1A1 966/4885 |
| US-20240408098-A1 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | KRAS, NRAS, HRAS | PRKDC 339/4885KDM4E 2874/4885ALDH1A1 3546/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | PRKDC 3092/4885KDM4E 3210/4885ALDH1A1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.